A large number of chemicals may exert adverse effects on the central and/or peripheral nervous system. A commonly recommended strategy for neurotoxicity testing is that of a tiered approach aimed at identifying and characterizing the neurotoxicity of a compound. Guidelines exist in the United States and other countries that define the tests to be utilized in tier 1 testing. To address problems related to the increasing cost and time required for toxicity testing, the increasing number of chemicals being developed, and the concern of animal welfare activists, attention is currently being devoted to in vitro alternatives. This paper addresses the use of in vitro systems in neurotoxicology, and their potential role in a general strategy for neurotoxicity testing. The advantages and disadvantages of in vitro approaches for mechanistic studies and for screening of neurotoxicants are discussed. Suggestions for further validation studies are proposed. Environ Hecalth Perspect 106(Suppi 2):505-510 (1998). 505-51Ocosta/abstract.html
Introduction
The nervous system is one of the most complex organ systems in terms of both structure and function. Nerve cells are unique in that they are not capable of regeneration after lethal damage, thus rendering the nervous system particularly vulnerable to toxic insult (1, 2) . Neurotoxicity is defined as "any adverse effect on the chemistry, structure and function of the nervous system during development or at maturity, induced by chemical or physical influences" (3) . The key issue is the interpretation of the word adverse, as there is not always agreement among scientists on what constitutes an adverse change. Issues that have been considered include the nature of the change (morphologic, neurochemical, neurologic, or behavioral), the degree of change, and whether the effect is transitory or persistent. A proposed definition of an adverse effect is "any treatment-related change which interferes with normal function and compromises adaptation to the environment" (4) .
Most morphologic changes such as neuronopathy, axonopathy, or myelinopathy would be considered adverse, even if the changes were mild or transitory. On the other hand, a transitory hypertrophy of astrocytes could be viewed as an adaptive, physiologic response (4) . However, one could argue that such an adaptive response may reflect prior damage to neuronal structures, and thus be a relevant biomarker of an adverse effect. Furthermore, a still-debated issue is whether neurochemical effects in the absence of structural damage should be considered adverse. Certainly an acute intoxication with an organophosphorus insecticide produces acute neurotoxic effects that tend to resolve with time. Additionally, repeated exposure to these compounds changes the homeostasis of the cholinergic system, altering the response to cholinergic drugs and possibly interfering with cognitive processes (5) . Similarly, acute response to solvents may cause only transient central nervous system effects, but these should be considered neurotoxic as they can lead to impaired function.
Another concept in neurotoxicity is the difference between direct and indirect effects on the nervous system. Damage to hepatic, renal, or pancreatic structures can result in secondary effects on the function and structure of the nervous system, such as encephalopathy or polyneuropathy. Secondary effects would not cause a substance to be considered neurotoxic; however, at very high doses, neurotoxicity would be evident. The identification of neurotoxic effects seen after administration of doses that exceed the maximum tolerated dose, or at which the normal metabolic processes of the body are severely compromised, is therefore a recognized problem (4) . Thus, a substance should be defined as neurotoxic when it or its metabolites produce adverse effects as a result of direct interactions with the nervous system. This paper briefly reviews some current approaches and methods of in vivo neurotoxicity testing and their advantages and limitations. It (29) .
If there is no evidence of a nervous system effect in tier 1 studies, then the substance can be considered as not neurotoxic. When, however, persistent effects on the nervous system are detected, the chemical can be considered a probable human neurotoxicant. In such cases, additional tests may be warranted in tier 2 and 3 studies to characterize the neurotoxic effects. The data from tier 1 studies should provide the basis for generation of specific hypotheses for subsequent studies and guide in the selection of the appropriate methods. The 
DevelopmenUl Neurotoxicity
The nervous system undergoes gradual development that continues well after birth in both animals and humans. On one hand, the developing nervous system can more readily adapt to, or compensate for, functional losses as a result of toxic insult; however, these may result in a delayed functional development. On the other hand, damage to the nervous system during key periods of brain development may result in long-term, irreversible damage. The absence of a fully developed bloodbrain barrier may result in the accumulation in the brain of certain chemicals in greater quantities than in adults. Special guidelines thus exist to determine developmental neurotoxicity. In principle, carefully conducted reproductive studies should be able to provide initial indications of potential developmental neurotoxicity. However, it has been shown that reliance on, for example, the Chernoff/Kavlock teratology assay as a primary developmental neurotoxicity screen could lead to a number of false negatives (30) . Current developmental neurotoxicity screening (9) includes a number of observations and measurements aimed at determining the development of proper motor sensory functions, learning, and memory, together with landmarks of physical development.
In Vitro Neurotoxicity Testing
The need to develop acceptable alternatives to conventional animal toxicity testing is increasingly recognized by toxicologists, to address problems related to the escalating costs and time required for toxicity assessment, the increasing number of chemicals being developed and commercialized, and the concern of animal-welfare activists (11, 12) . In the past several years, a number of publications have addressed issues related to the use of in vitro systems for neurotoxicity testing; they are reviewed here only briefly (11, (13) (14) (15) (16) (17) (18) .
In vitro testing procedures have several practical advantages; yet, the limitations of such approaches should also be outlined, particularly in the field of neurotoxicology, because of the complexity of the nervous system. To date, in vitro systems have been used extensively to study the mechanism of action of neurotoxic agents. However, their use in hazard identification in human health risk assessment has not been explored to any great extent (19) . Data generated from in vitro procedures are based on simplified approaches that require less time and cost to yield information (two clear advantages), but that do not take into account the distribution of the toxicant in the body, the route of administration, and the metabolism of the substance (19) . In addition, it is difficult to extrapolate in vitro toxicity data to animal or human neurotoxicity end points such as sensory disorders or cognitive impairment. Several in vitro systems are currently being evaluated for their ability to predict the neurotoxicity of various agents seen in intact animals, and an important part of this process should be the detection of false negatives. Until this process proves satisfactory, a cautious view should be that outlined recently by the U.S. EPA in their proposed guidelines for neurotoxicity risk assessment: "Demonstrated neurotoxicity in vitro in the absence of in vivo data is suggestive but inadequate evidence of a neurotoxic effect. On the other hand, in vivo data supported by in vitro data enhance the reliability of the in vivo results" (19) .
What (20) . Primary cultures of cortical, cerebellar. or hippocampal neurons are being widely used to study mechanisms of excitotoxicity (16) 
In Vitro Systems for
Neurotoxicity Screening A goal of in vitro systems is that of providing a quick and inexpensive way for assessing potential neurotoxicity. Several approaches have been proposed to identify neurotoxicants and to distinguish them from cytotoxicants, as well as to rank neurotoxicants for toxic potency (11, 13) . Screening is by definition a first-tier evaluation of chemicals that will be followed by additional more specific and complex tests. The same criteria for in vitro screening approaches for other end points of toxicity also apply to the neurotoxicity screening; they are a) low incidence of false negatives and false positives; b) high correlation with in vivo toxicity data; and c) sensitive, simple, rapid, economical, and versatile. As indicated by many scientists, the challenge in developing in vitro systems for neurotoxicity is that of differentiating cytotoxicants from neurotoxicants. Because any cell culture system poorly mimics the intact nervous system, it is important to utilize a variety of in vitro models and a multiplicity of end points to parallel, at least in part, neurotoxicity in the whole animal (11) . Although the use of a test battery is always advocated and recommended, the choice of the systems to be used has not yet been defined, as various investigators have proposed different though similar approaches (14, 18) . A basic initial test battery should include a neuronal and a glial cell line, possibly of human origin, one nonneuronal cell line, and a slightly more complex system such as the rat primary micromass (21) (22, 23) .
End points to be measured in in vitro tests should include indicators of cytotoxicity and viability as well as neurotoxicity. Morphologic end points such as neurite extension can also be measured and quantified (24) . If neurotoxicity end points are affected at concentrations lower than those producing cytotoxic effects, a chemical can be considered a potential neurotoxicant. The concern, however, remains that the neurotoxic end points representing the target for a certain chemical may have been missed by the assays chosen for the neurotoxicity screening, thus generating a false negative result.
A number of considerations should be made with regard to potential problems related to experimental design and technical aspects of in vitro neurotoxicity tests, all of which indicate the need for a strict standardization of experimental procedures. For example, the source and passage of the cell line, the cell density, the effect of solvent, the source and composition of the media, and the duration of exposure are all potential sources of error. The fact that several chemicals must be metabolized to active toxicants may be good motivation to include microsomal preparations (the S9 fraction) to the test system, as is routinely done, for example, in the Ames test for mutagenicity. However, even these preparations need to be carefully standardized.
The 
Future Perspectives
One of the goals of in vitro testing for toxicants should be that of reducing the use of animals rather then replacing them for toxicity testing (27) . As It is highly unlikely that a single test will be developed for neurotoxicity. The suggested battery of tests offers some promise. However, as a screening device, practicality will necessarily limit the number of end points that can be measured, with the ensuing risk of generating potential false negatives. Before a battery of in vitro tests can be taken into serious consideration as an alternative, a large validation study should be carried out; several laboratories from different countries should be involved in the testing of several hundred compounds. Such effort, and the necessary funding, can only come from a common action of European, North American, and other regulatory and scientific agencies, institutions, and foundations. National and international agencies and scientific organizations should promote the formation of a panel of neurotoxicologists and statisticians who would meet, following a series of discussions and perhaps additional pilot studies, to define the nature of the battery (cell types, end points), and oversee the completion of the large validation experiment. Such a validated in vitro battery could serve as the basis for prioritization of chemicals for further in vivo testing.
In the meantime, in vitro approaches can be useful as screening tools for particular situations or classes of compounds. For example, cells expressing acetylcholinesterase or neuropathy target esterase have been used to screen for the inhibitory potency of organophosphorus esters and may be useful as predictors of acute cholinergic toxicity versus delayed neurotoxicity (28) . As previously mentioned, in vitro systems are very useful in studying mechanisms of neurotoxicity, and represent an important component of all stages of toxicity testing.
In summary, it is tempting to conclude that neurotoxicology does not offer much promise in terms of the development of alternatives to the current testing procedures. Certainly, the road may be more difficult than for other, less complex, target organs. However, a large concerted effort to launch the validation process, and to go beyond the necessarily incomplete and fragmented attempts so far, would be of great benefit. With the results of such efforts in hand, the scientific and regulatory communities would be able to decide whether sufficient confidence can be placed in such an alternative approach and to define its role in a concerted testing strategy, or whether in vitro tests should be confined for use in specific situations or in mechanistic studies in neurotoxicology.
